This is covered in this proposal:
The Pharmaceutical Accountability and Transparency Act (PATA)
I would love to include more investigative information to flesh out the problems with incentivizing, kickbacks, etc. to make the proposal more inclusive of all the problems and the necessary solutions to address those problems.